Gemita Indications/Uses

Non-Small Cell Lung Cancer: Gemcitabine is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer.
Pancreatic Cancer: Gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine is indicated in patients previously treated with 5-FU.
Breast Cancer: Gemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
Bladder Cancer: Gemcitabine in combination with cisplatin is indicated for treatment of patients with bladder cancer.
Ovarian Cancer: Gemcitabine, alone or in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed following platinum-based therapy.
Biliary Tract Cancer: Gemcitabine is indicated for treatment of patients with biliary tract cancer.
Cervical Cancer: Gemcitabine is indicated for treatment of patients with locally advanced cervical cancer in combination therapy with radiation and cisplatin.